815 related articles for article (PubMed ID: 19793665)
1. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
2. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
3. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
Boomsma JM; van Dussen L; Wiersma MG; Groener JE; Aerts JM; Maas M; Hollak CE
Blood Cells Mol Dis; 2010 Mar; 44(3):181-7. PubMed ID: 20074983
[TBL] [Abstract][Full Text] [Related]
5. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
6. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
7. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
[TBL] [Abstract][Full Text] [Related]
8. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
9. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
[TBL] [Abstract][Full Text] [Related]
10. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis.
Kaplan P; Andersson HC; Kacena KA; Yee JD
Arch Pediatr Adolesc Med; 2006 Jun; 160(6):603-8. PubMed ID: 16754822
[TBL] [Abstract][Full Text] [Related]
11. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease.
Drugan C; Jebeleanu G; Grigorescu-Sido P; Caillaud C; Craciun AM
Blood Cells Mol Dis; 2002; 28(1):13-20. PubMed ID: 11814307
[TBL] [Abstract][Full Text] [Related]
12. [French results of enzyme replacement therapy in Gaucher's disease].
Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
[TBL] [Abstract][Full Text] [Related]
13. Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy.
Zevin S; Abrahamov A; Hadas-Halpern I; Kannai R; Levy-Lahad E; Horowitz M; Zimran A
Q J Med; 1993 Sep; 86(9):565-73. PubMed ID: 8255971
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of Gaucher patients with a novel chitotriosidase assay.
Schoonhoven A; Rudensky B; Elstein D; Zimran A; Hollak CE; Groener JE; Aerts JM
Clin Chim Acta; 2007 Jun; 381(2):136-9. PubMed ID: 17408605
[TBL] [Abstract][Full Text] [Related]
15. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.
Mistry PK; Lukina E; Ben Turkia H; Amato D; Baris H; Dasouki M; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Shankar S; Solano MH; Ross L; Angell J; Peterschmitt MJ
JAMA; 2015 Feb; 313(7):695-706. PubMed ID: 25688781
[TBL] [Abstract][Full Text] [Related]
16. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention.
Mistry PK; Sadan S; Yang R; Yee J; Yang M
Am J Hematol; 2007 Aug; 82(8):697-701. PubMed ID: 17492645
[TBL] [Abstract][Full Text] [Related]
17. Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone.
Mikosch P
Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):665-81. PubMed ID: 22142746
[TBL] [Abstract][Full Text] [Related]
18. Enzyme replacement therapy for Gaucher disease in Australia.
Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
[TBL] [Abstract][Full Text] [Related]
19. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients.
Poll LW; Koch JA; Willers R; Aerts H; Scherer A; Häussinger D; Mödder U; vom Dahl S
Blood Cells Mol Dis; 2002; 28(2):209-20. PubMed ID: 12064917
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
